Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: J Clin Psychopharmacol. 2015 Aug;35(4):389–395. doi: 10.1097/JCP.0000000000000351

Table 1. Outcome Measures by Treatment.

Measure Total
(N=85)		 Treatment Analysis
Placebo
(N=29)		 Estradiol
(N=26)		 Sertraline
(N=30)		 Test statistic p
Exit SIGH-ADS29 13.2 ± 7.84 13.1 ± 8.41 14.7 ± 8.78 12.1 ± 6.36 H(2) = 0.95 0.62
% SIGH-ADS29 change 45 ± 29.3 48 ± 29.8 38 ± 33.7 49 ± 24.1 F(2,0) =1.19 0.31
Response (%SIGH-ADS29 change ≥50) 47 (55.3) 17 (58.6) 11 (42.3) 19 (63.3) χ2(2) = 2.69 0.26
Remission (Exit SIGH-ADS29 ≤ 8) 25 (29.4) 9 (31.0) 7 (26.9) 9 (30.0) χ2(2) = 0.12 0.94

Abbreviations: SIGH-ADS=Structured Interview Guide for the Hamilton Depression Rating Scale With Atypical Depression Supplement; H=the equivalent of the Mann-Whitney U test for 3 or more groups.